Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer, Gerd;Nelson, Mark;Lazzarin, Adriano;Konourina, Irina;van der Ryst, Elna;et.al.
(2008) The New England journal of medicine —

Files

No attached file found for this publication.

Details

Authors
  • Fätkenheuer, Gerd
    Author
  • Nelson, Mark
    Author
  • Lazzarin, Adriano
    Author
  • Konourina, Irina
    Author
  • van der Ryst, Elna
    Author
Show more
Abstract
We conducted subanalyses of the combined results of the Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 studies to better characterize the efficacy and safety of maraviroc in key subgroups of patients.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Fätkenheuer, G., Nelson, M., Lazzarin, A., Konourina, I., Hoepelman, A. I. M., Lampiris, H., Hirschel, B., Tebas, P., Raffi, F., Trottier, B., Bellos, N., Saag, M., Cooper, D. A., Westby, M., Tawadrous, M., Sullivan, J. F., Ridgway, C., Dunne, M. W., Felstead, S., et al. (2008). Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. The New England journal of medicine. https://doi.org/10.1056/NEJMoa0803154